NTPC Green Energy IPO - Day 1 Subscription at 0.14 Times
Emcure Pharmaceuticals IPO - Lists 31.45% up on NSE and BSE
Last Updated: 10th July 2024 - 11:56 am
Strong listing for Emcure Pharmaceuticals IPO in NSE
Emcure Pharmaceuticals had a strong listing on 10th July 2024, listing at ₹1,325.05 per share, a premium of 31.45% over the issue price of ₹1,008 per share. Here is the pre-open price discovery for the Mainboard Emcure Pharmaceuticals IPO on the NSE as of 9.50 am.
PRE-OPEN ORDER COLLECTION SUMMARY
Indicative Equilibrium Price (In ₹) | 1,325.05 |
Indicative Equilibrium Quantity (Number of Shares) | 25,16,732 |
Final Price (In ₹) | 1,325.05 |
Final Quantity (Number of Shares) | 25,16,732 |
Previous Close (Final IPO price) | ₹1,008.00 |
Discovered Listing Price premium / discount to IPO Price (₹) | ₹+317.05 |
Discovered Listing Price premium / discount to IPO Price (%) | +31.45% |
Data Source: NSE
The mainboard IPO of Emcure Pharmaceuticals was a book built IPO with a price band of ₹960 to ₹1,008 per share. The price was discovered at the upper end of the band at ₹1,008 per share after a robust subscription response of over 67X and the anchor allocation also happening at the upper band of ₹1,008 per share, a day ahead of the IPO opening. On 10th July 2024, the stock of Emcure Pharmaceuticals listed on the NSE Mainboard segment at a price of ₹1,325.05 per share, a premium of 31.45% over the IPO issue price of ₹1,008. For the day, the upper circuit price has been set at ₹1,457.55 and the lower circuit price has been set at ₹1,192.55.
As of 10.12 am, the volumes were 77.09 lakh shares while the turnover (value) was at ₹1,041.88 crore on NSE. The stock has a face value of ₹10 per share and the applicable margin rate is 25.00%. The opening market cap of the stock stands at ₹26.006 crore. The stock will be traded in the EQ series with delivery and intraday trades permitted, but part of the rolling segment cycle of the NSE. Trading shall be in the Normal Market segment – Compulsory Demat (Rolling Settlement) for all investors. At 10.12 am, it is trading higher at ₹1,375.25 per share; which is 3.79% above the listing price. The stock of Emcure Pharmaceuticals trades with the following symbols; NSE Code (EMCURE), BSE Code (544210), and the shares have been credited to the demat accounts of allottees under the designated ISIN (INE168P01015)
How Emcure Pharmaceuticals listed on BSE?
Here is a quick price discovery summary of Emcure Pharmaceuticals on the Bombay Stock Exchange (BSE) on the day of listing, 10th July 2024. The pre-IPO period ends at 9.50 am and actual trading on the IPO stock starts at 10.00 am on listing day.
PRE-OPEN ORDER COLLECTION SUMMARY
Indicative Equilibrium Price (In ₹) | 1,325.05 |
Indicative Equilibrium Quantity (Number of Shares) | 1,81,015 |
Final Price (In ₹) | 1,325.10 |
Final Quantity (Number of Shares) | 1,81,015 |
Previous Close (Final IPO price) | ₹1,008.00 |
Discovered Listing Price premium / discount to IPO Price (₹) | ₹+317.05 |
Discovered Listing Price premium / discount to IPO Price (%) | +31.45% |
The Mainboard IPO of Emcure Pharmaceuticals was a book built IPO priced at the upper end of the band at ₹1,008 per share. On 10th July 2024, the stock of Emcure Pharmaceuticals listed on the BSE mainboard segment at a price of ₹1,325.05 per share, a premium of 31.45% over the IPO issue price of ₹1,008. For the day, the upper circuit price has been set at ₹1,457.55 and the lower circuit price has been set at ₹1,192.55. As of 10.13 am, the volumes were 6.71 lakh shares while the turnover (value) was at ₹90.71 crore on BSE. The stock has a face value of ₹10 per share. The stock will be traded in the regular EQ segment of the BSE in T+1 settlement cycle. The market cap of the stock stands at ₹26.023 crore while the free float market cap of the stock stands at ₹1,822 crore. At 10.13 am, the stock is trading 3.77% higher at ₹1,375.00 per share on the BSE.
Trending on 5paisa
05
5paisa Research Team
Discover more of what matters to you.
IPOs Related Articles
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.